The comment period opened by MOFCOM and MOST Announcement No. 48 of 2026 closes on 15 November 2026. During this window companies face an unusual dual-track position: a pre-export registration duty that is already in force, alongside a catalogue revision that is not yet final but will determine the long-term procedure. Most commentary stops at whether to register. The question that actually affects delivery schedules is what happens afterwards — whether the same technology will be handled by filing or by licensing once the catalogue lands.

The Catalogue of Technologies Prohibited or Restricted from Export divides technologies into two categories: prohibited and restricted. The division is not a label; it corresponds to three entirely different procedures.

Technology on the prohibited list cannot be exported at all — there is no licence route. Technology on the restricted list requires approval from the commerce authorities, with a review period and a real possibility of refusal. Technology outside the catalogue is subject to contract registration for technology export, which is recordal in nature and generally does not determine whether the transaction can proceed.

Announcement No. 48 addresses only the addition of items: 23 AI technologies, five biopharma technologies and twelve solar technologies. Whether those 40 items end up prohibited or restricted is not stated; the annex’s scope and indicators are what will drive the analysis. In other words, companies can now determine only whether a technology is under discussion, not which procedure will apply later. Treating the two as the same is the most common misreading at present.

Registration is not a licence, and a licence is not a registration

Interim registration is information reporting: basic details of the exporter and recipient, destination, the technology and its intended use, and estimated value. It does not examine the substance of the transaction and confers no approval.

A licence is substantive review, covering the technology itself, the end user and end use, and the impact on national security and industrial competitiveness, with a timeline measured in months. A company that plans delivery on a registration timetable will find its schedule out of alignment the moment the formal catalogue takes effect and the procedure shifts to licensing.

The reverse mistake also occurs: having filed a registration, some companies assume the licence will follow as a matter of course. There is no automatic link between the two. The registration record can support an application; it is not a preliminary approval.

What the three-week window can actually change

For a specific company, the window allows more than it appears.

First, check the technical indicators. The annex sets out scope and indicators; a company can compare its own technology item by item to see whether it is accurately covered, over-covered, or omitted. Where an indicator does not match industry reality, or a capability has become generic across the sector, a submission can be made before 15 November through the designated email, fax or letter, with technical explanations and evidence. Adoption is not guaranteed, but this is the only formal channel.

Second, ask for facilitation measures. The announcement already provides that, for biopharma, outbound licensing arrangements that do not transfer ownership benefit from expedited measures such as automatic licensing. The AI section has no equivalent. Companies whose business is predominantly licensing rather than assignment have a concrete point to raise, and it is often worth more than arguing over an individual indicator.

Third, build the transition into contracts. For cross-border technology contracts in performance or about to be signed, allocate who handles registration and any subsequent licence, on what timetable, and what happens if a licence is refused — including the consequences for delivery and an exit mechanism. For clause design, see commercial contracts.

A maintained register beats a one-off inventory

Most companies respond to an announcement like this with a single inventory, then file it away. The problem is that the catalogue, the indicators and licensing practice keep moving; a one-off inventory goes stale quickly.

A better approach is a standing technology export register: for each product or project, record the technology elements, whether they are open-sourced, who owns the rights, the recipient and destination, the current procedural status (not applicable / registered / licence applied for), and the next review date. Its value shows up at three moments — when the formal catalogue takes effect, when the next revision begins, and at compliance sign-off before closing a transaction.

For companies operating in several jurisdictions, the register also needs to be mapped against the foreign side’s control lists, so that a filing in China does not sit alongside an unmet licence requirement abroad, or two authorities classify the same technology differently. For a comparison methodology, see multi-jurisdiction compliance.

Existing and new business need different treatment

The most commonly overlooked point in a transition period is legacy business. The announcement expressly brings exports already begun but not completed within the registration scope. Live overseas delivery projects therefore need a look back: does the technology fall within the annex, has it been registered, and do the remaining delivery stages introduce new technology elements?

New business can price the procedural cost in at the design stage. Deciding the export route when the product plan is set saves time compared with an assessment after signing, and avoids underquoting compliance costs at proposal stage. For route analysis, see export controls; for a full walkthrough of the announcement, see China proposes 23 AI technologies for export control.

This article is based on publicly available information from MOFCOM and MOST Announcement No. 48 of 2026. It is provided for general information only and does not constitute legal advice. The final classification, indicators and licensing procedures are subject to the formally issued catalogue and the competent authorities’ guidance.